Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Blood (2024) 144 (Supplement 1): 1927.1.

https://doi.org/10.1182/blood-2024-200529

Published: 2024

Journal Articles

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Blood (2024) 144 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2024-201076

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Blood (2023) 142 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2023-182042

Published: 2023

Journal Articles

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Merav Leiba, MD, Krzysztof Jamroziak, MD PhD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4354.

https://doi.org/10.1182/blood-2019-132193

Published: 2019

Journal Articles

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Marcin M Machnicki, MSc, Patryk Górniak, Monika Pepek, MSc, Agnieszka Szymczyk, Elżbieta Iskierka-Jażdżewska, Pawel Steckiewicz, Aleksandra Bluszcz, Malgorzata Rydzanicz, PhD, Marek Hus, Rafal Ploski, MD PhD, Przemyslaw Juszczynski, Prof., MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Jamroziak, MD PhD, Bartosz Pula

Blood (2019) 134 (Supplement_1): 5456.

https://doi.org/10.1182/blood-2019-124693

Published: 2019

Journal Articles

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Blood (2019) 134 (Supplement_1): 4180.

https://doi.org/10.1182/blood-2019-125864

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Journal Articles

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Krzysztof Jamroziak, Krzysztof Giannopoulos, Tomasz Wrobel, MD PhD, Adam Nowicki, Bartosz Pula, Norbert Grząśko, Justyna Rybka, Paweł J. Robak, MD, Agnieszka Druzd-Sitek, Adam Walter-Croneck, Katarzyna Brzeźniakiewicz-Janus, MDPhD, Jarosław Czyż, Krzysztof Warzocha, Dominik Dytfeld

Blood (2017) 130 (Supplement 1): 5404.

https://doi.org/10.1182/blood.V130.Suppl_1.5404.5404

Published: 2017

Journal Articles

Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry

Joanna Gora Tybor, Tomasz Sacha, Joanna Waclaw, Joanna Niesiobedzka-Krezel, Olga Grzybowska-Izydorczyk, Ewa Medras, Izabela Deren-Wagemann, Elzbieta Patkowska, Ilona Seferynska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Watek, Ewa Wasilewska, Tomasz Stoklosa, Krzysztof Warzocha, Krzysztof Jamroziak

Blood (2017) 130 (Supplement 1): 2887.

https://doi.org/10.1182/blood.V130.Suppl_1.2887.2887

Published: 2017

Journal Articles

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry

Joanna Gora-Tybor, Tomasz Sacha, Joanna Waclaw, Joanna Niesiobedzka, Olga Grzybowska-Izydorczyk, Ewa Medras, Izabela Deren-Wagemann, Elzbieta Patkowska, Ilona Seferynska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Watek, Krzysztof Warzocha, Krzysztof Jamroziak

Blood (2016) 128 (22): 1909.

https://doi.org/10.1182/blood.V128.22.1909.1909

Published: 2016

Journal Articles

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Blood (2014) 124 (21): 2044.

https://doi.org/10.1182/blood.V124.21.2044.2044

Published: 2014

Journal Articles

Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML)

Anna Stepien, MSc, Alessandro Martino, PhD, Federico Canzian, PhD, Daniele Campa, PhD, Angelika Stein, Joanna Gora-Tybor, MD PhD, Tomasz Sacha, MD PhD, Dorota Link-Lenczowska, PhD, Izabela Florek, PhD, Witold Prejzner, MD PhD, Zofia Specht-Szwoch, Malgorzata Calbecka, MD PhD, Marcin Rymko, MD PhD, Marek Dudzinski, MD PhD, Pawel Gaj, PhD, Tadeusz Robak, MD, Krzysztof Warzocha, MD PhD, Krzysztof Jamroziak, MD PhD

Blood (2014) 124 (21): 5222.

https://doi.org/10.1182/blood.V124.21.5222.5222

Published: 2014

Journal Articles

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Blood (2014) 124 (21): 3421.

https://doi.org/10.1182/blood.V124.21.3421.3421

Published: 2014

Journal Articles

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Blood (2014) 124 (21): 3628.

https://doi.org/10.1182/blood.V124.21.3628.3628

Published: 2014

Journal Articles

High Expression Of Cereblon ( CRBN ) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia

Krzysztof Jamroziak, MD, PhD, Janusz Szemraj, PhD, Tadeusz Robak, MD, PhD, Krzysztof Giannopoulos, MD, PhD

Blood (2013) 122 (21): 4934.

https://doi.org/10.1182/blood.V122.21.4934.4934

Published: 2013

NARROW

Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Preemptive Daratumumab Therapy for Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma: Rationale and Design of the Polish Myeloma Consortium Predator Study

Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML)

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

High Expression Of Cereblon ( CRBN ) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only